What is Glaukos Corp?
Headquartered in Aliso Viejo, California, Glaukos Corporation is a specialized ophthalmic pharmaceutical and medical technology firm. The company is primarily recognized for its innovative approach to treating glaucoma, corneal disorders, and retinal diseases. Its core product portfolio, including the iStent and iStent inject W, utilizes micro-bypass technology to enhance aqueous humor outflow during cataract surgery. Furthermore, the company is actively developing advanced therapies such as iDose TR, an intracameral procedural pharmaceutical designed to manage intraocular pressure. By maintaining a direct sales organization and a global distribution network, Glaukos has solidified its market position as a critical provider of surgical and pharmaceutical solutions for patients suffering from open-angle glaucoma and ocular hypertension.
How much funding has Glaukos Corp raised?
Glaukos Corp has raised a total of $187.3M across 4 funding rounds:
Series A
$10M
Series D
$35M
Series F
$30M
Stock Offering
$112.3M
Series A (2002): $10M with participation from Versant Ventures, Domain Associates, and Frazier Healthcare Partners
Series D (2008): $35M led by InterWest Partners, Frazier Healthcare Partners, Montreux Equity Partners, Domain Associates, OrbiMed, Versant Ventures, and Fjord Ventures
Series F (2013): $30M supported by Versant Ventures, Meritech, Domain Associates, OrbiMed, InterWest Partners, Frazier Healthcare Partners, and Montreux Equity Partners
Stock Issuance/Offering (2015): $112.3M, investors not publicly disclosed
Key Investors in Glaukos Corp
Versant Ventures
A prominent VC firm specializing in early-stage biotechnology, known for managing significant capital and fostering innovation through extensive academic and scientific partnerships.
Domain Associates
An investment advisory firm established in 1985 with a deep focus on the biopharmaceutical and medical device sectors, boasting a track record of numerous successful IPOs.
OrbiMed
A specialized healthcare investment firm that manages capital across the entire life sciences spectrum, providing strategic guidance to companies from early-stage development to commercial scaling.
What's next for Glaukos Corp?
With a solid foundation of capital, Glaukos is well-positioned to accelerate the commercialization of its late-stage pipeline, particularly the iDose TR platform. The strategic focus remains on expanding the clinical utility of its existing stent technologies while simultaneously navigating the regulatory pathways for new therapeutic agents. As the company continues to scale, the emphasis will likely shift toward deepening its international market penetration and leveraging its existing infrastructure to drive operational efficiencies. The ongoing support from long-term institutional partners provides the necessary runway to sustain innovation in the highly competitive ophthalmic space, ensuring that Glaukos remains at the forefront of medical device and pharmaceutical convergence.
See full Glaukos Corp company page
